Pharma blockbusters, pandemic policy, & legal chicanery
Is the next Lipitor on the way? When is a pandemic over-over? And what’s a Texas two-step? All that and more on the new episode of “The Readout LOUD” #podcast.
Related Articles
Second-generation mosquito nets prevented 13 million malaria cases in large pilot programs
Second-generation mosquito nets prevented 13 million malaria cases and 25,000 deaths in large pilot programs.
H5N1 bird flu in U.S. cattle: A wake-up call to action
Comparisons to seasonal flu management underestimate the unique challenges posed by H5N1 bird flu.
Health disparities and premature deaths run deep, even in best-performing states
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Kids can’t wait any longer for social media safety
Millions of children are coming of age in an unrestricted and unprotected digital universe. They need guardrails that can keep them safe.
USDA faulted for disclosing scant information about outbreaks of H5N1 avian flu in cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Nominate a 2024 STAT Wunderkind
Nominate a 2024 STAT Wunderkind STAT Wunderkinds is a chance to celebrate early-career researchers who are not yet independent scientists or program
Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
Biocon is developing a generic version of Novo Nordisk’s Wegovy and is prepared to conduct a clinical trial next year if needed.
New antibiotics were underprescribed for hard-to-treat infections, study finds
Newer antibiotics were underprescribed for hard-to-treat infections, a new study finds.